Gefitinib is another tyrosine kinase inhibitor, and its combination with EGCG could enhance the inhibition of tumor migration and invasion by decreasing enzymatic activity of tyrosine kinase and the expression of MMP-2, and suppressing the phosphorylation of ERK, JNK, p38, and AKT. This evidence concerns the gene AKT1 and neoplasm.